NCT02751710View on ClinicalTrials.gov

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

369

Participants

Timeline

Start Date

December 6, 2016

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)Stage IIb Breast Cancer (T3N0)
Interventions
OTHER

Whole-body FDG PET-CT alone

FDG PET-CT imaging

Trial Locations (6)

L8V 5C2

Juravinski Cancer Centre, Hamilton

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital Regional Cancer Centre, Ottawa

P7B 6V4

Thunder Bay Regional Health Sciences Centre, Thunder Bay

M4N 3M5

Sunnybrook Odette Cancer Centre, Toronto

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

Cancer Care Ontario
All Listed Sponsors
collaborator

Cancer Care Ontario

OTHER

lead

Ontario Clinical Oncology Group (OCOG)

OTHER